Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib by Tracy E. Wiczer, Lauren B. Levine, Jessica.

Published byMaarten Devos Modified over 5 years ago

Similar presentations

Presentation on theme: "Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib by Tracy E. Wiczer, Lauren B. Levine, Jessica."— Presentation transcript:

1 Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib by Tracy E. Wiczer, Lauren B. Levine, Jessica Brumbaugh, Jessica Coggins, Qiuhong Zhao, Amy S. Ruppert, Kerry Rogers, Anli McCoy, Luay Mousa, Avirup Guha, Nyla A. Heerema, Kami Maddocks, Beth Christian, Leslie A. Andritsos, Samantha Jaglowski, Steven Devine, Robert Baiocchi, Jennifer Woyach, Jeffrey Jones, Michael Grever, Kristie A. Blum, John C. Byrd, and Farrukh T. Awan BloodAdv Volume 1(20): September 12, 2017 © 2017 by The American Society of Hematology

2 Tracy E. Wiczer et al. Blood Adv 2017;1:1739-1748
© 2017 by The American Society of Hematology

3 Study population. Study population.
Tracy E. Wiczer et al. Blood Adv 2017;1: © 2017 by The American Society of Hematology

4 AF incidence. AF incidence. (A) Cumulative incidence of AF in patients receiving ibrutinib. (B) Cumulative incidence of AF based on history of AF. Tracy E. Wiczer et al. Blood Adv 2017;1: © 2017 by The American Society of Hematology

5 AF risk factor analysis.
AF risk factor analysis. (A) Univariable analysis for AF risk factors for entire population. (B) Multivariable analysis for AF risk factors for entire population. PS, performance status. Tracy E. Wiczer et al. Blood Adv 2017;1: © 2017 by The American Society of Hematology

Download ppt "Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib by Tracy E. Wiczer, Lauren B. Levine, Jessica."

Similar presentations

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.
Nyla A. Heerema The Ohio Sate University

Nyla A. Heerema The Ohio Sate University
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.
Risk Factors for Rehospitalization for Acute Coronary Syndromes and Unplanned Revascularization Following Acute Myocardial Infarction by Suzanne V. Arnold,

Risk Factors for Rehospitalization for Acute Coronary Syndromes and Unplanned Revascularization Following Acute Myocardial Infarction by Suzanne V. Arnold,
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation by Christopher Bredeson, Jennifer.

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation by Christopher Bredeson, Jennifer.
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,
Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.

Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.
Umbilical cord blood transplantation and cytomegalovirus: posttransplantation infection and donor screening by Maria S. Albano, Patricia Taylor, Robert.

Umbilical cord blood transplantation and cytomegalovirus: posttransplantation infection and donor screening by Maria S. Albano, Patricia Taylor, Robert.
Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura
Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group by.

Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group by.
The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.
How I treat elderly patients with myeloma

How I treat elderly patients with myeloma
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,
The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve.

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve.
A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.

A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease by Sten Myrehaug, Melania Pintilie, Lingsong.
Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.

Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.

Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.

Similar presentations

Ads by Google